These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 22916844)
1. High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring. Bernlochner I; Mayer K; Morath T; Braun S; Schulz S; Schömig A; Koch W; Kastrati A; Sibbing D Platelets; 2013; 24(6):500-2. PubMed ID: 22916844 [No Abstract] [Full Text] [Related]
2. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056 [TBL] [Abstract][Full Text] [Related]
3. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219 [TBL] [Abstract][Full Text] [Related]
4. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB; Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867 [TBL] [Abstract][Full Text] [Related]
5. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367 [TBL] [Abstract][Full Text] [Related]
6. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573 [TBL] [Abstract][Full Text] [Related]
8. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Braun OÖ; Angiolillo DJ; Ferreiro JL; Jakubowski JA; Winters KJ; Effron MB; Duvvuru S; Costigan TM; Sundseth S; Walker JR; Saucedo JF; Kleiman NS; Varenhorst C Thromb Haemost; 2013 Dec; 110(6):1223-31. PubMed ID: 24009042 [TBL] [Abstract][Full Text] [Related]
9. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient). Wynn RL Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886 [No Abstract] [Full Text] [Related]
10. Response to antiplatelet treatment: from genes to outcome. Giusti B; Abbate R Lancet; 2010 Oct; 376(9749):1278-81. PubMed ID: 20801497 [No Abstract] [Full Text] [Related]
11. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027 [TBL] [Abstract][Full Text] [Related]
12. Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial". Alexopoulos D; Xanthopoulou I Circ Cardiovasc Interv; 2013 Feb; 6(1):e11. PubMed ID: 23424274 [No Abstract] [Full Text] [Related]
13. Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. Lala A; Berger JS; Sharma G; Hochman JS; Scott Braithwaite R; Ladapo JA J Thromb Haemost; 2013 Jan; 11(1):81-91. PubMed ID: 23137413 [TBL] [Abstract][Full Text] [Related]